|
COPYRIGHT 2004 Houston Chronicle
Byline: Todd Ackerman
Dec. 9--A newer breast cancer drug that outperforms industry-standard tamoxifen should replace it as first-line therapy for postmenopausal patients, according to a new international study.
The University of Texas M.D. Anderson Cancer Center and other researchers reported Wednesday that women who took Arimidex were less likely to have their breast cancer come back, less likely to have it spread and less likely to have serious side effects.
"I hope with this new data doctors start using Arimidex as their new first choice," said Dr. Aman Buzdar, a professor in M.D. Anderson's department of breast medical oncology and the lead investigator...
Read the full article for free courtesy of your local library.
| 
Bookmark this article
Print this article
Link to this article
Email this article
Digg It!
Add to del.icio.us
RSS
